Incyte has announced positive results from a pivotal study of tafasitamab (Monjuvi®) in relapsed or refractory follicular lymphoma.
Based on these positive results, Incyte expects to file a supplemental Biologics License Application for tafasitamab for the treatment of patients with follicular lymphoma who have failed at least one prior systemic anti-CD20 immunotherapy or chemo-immunotherapy by the end of the year.
Earlier this year, Incyte gained exclusive global development and commercialisation rights to Monjuvi® (tafasitamab).